Related by context. All words. (Click for frequent words.) 72 tumor histology 70 breast cancer subtypes 69 molecular abnormalities 69 HER2 positive cancers 69 nodal metastasis 69 mTOR inhibitors 68 prostate cancer CaP 68 genomic alterations 68 EGFR tyrosine kinase inhibitors 68 cisplatin resistant 68 EGFR antibodies 68 histological subtype 67 NSCLC tumors 67 molecular biomarkers 67 KRAS mutation 67 K ras mutations 67 prognostic markers 67 molecular determinants 67 FGFs 66 gefitinib Iressa 66 CYT# potent vascular disrupting 66 prognostic indicators 66 histologies 66 kinase inhibition 66 gastric carcinomas 66 antitumor effect 66 mitochondrial toxicity 66 lymphoid tumors 66 HER2 expression 66 molecular subtypes 66 antimetastatic 66 breast carcinoma 66 antimitotic 66 antiangiogenic therapy 66 hypermethylated 66 SERMs 66 anti angiogenic agents 66 EGFR pathway 66 antiangiogenic agent 66 druggable targets 66 HER2 overexpression 66 KRAS oncogene 66 hematopoietic cancers 66 hormone receptor status 66 histone deacetylases 66 metastatic neuroendocrine tumors 66 Smac mimetic 66 anti angiogenic drugs 66 antiangiogenic agents 66 ovarian carcinoma 65 potent antiproliferative 65 PKCi 65 metastatic lymph nodes 65 molecularly targeted 65 tumor subtype 65 susceptibility loci 65 endocrine therapies 65 Prognostic factors 65 pharmacodynamic markers 65 microtubule targeting 65 renal carcinoma 65 biologic pathways 65 endometrial cancers 65 telomerase inhibition 65 epithelial tumors 65 PIK3CA 65 galiximab 65 prognostic biomarker 65 genetic polymorphisms 65 HIV HCV coinfected 65 biomarker identification 65 EGFR TKIs 65 genetic determinants 65 hormone refractory 65 Symadex 65 invasive carcinoma 65 xenograft models 65 MAGE A3 ASCI 65 miRNA expression 65 splice variants 65 antiangiogenesis 65 trans retinoic acid 65 chemopreventive agent 65 LHRH receptor positive 65 clinicopathological 65 radionuclide therapy 65 diagnostic biomarker 65 cytostatic 65 ALK mutations 65 histone deacetylase inhibitor 65 Smac mimetics 64 KRAS mutations 64 pancreatic adenocarcinoma 64 pharmacokinetic interactions 64 MEK inhibitors 64 etiologic 64 B7 H3 64 myeloproliferative diseases 64 squamous cell lung cancer 64 Gleevec resistant 64 histologic subtype 64 flavopiridol 64 Cloretazine 64 chlamydial infection 64 underlying pathophysiology 64 gastric cardia 64 neratinib 64 HNSCC 64 pancreatic prostate 64 antiproliferative effects 64 BRCA mutation carriers 64 miRNA molecules 64 gene rearrangements 64 tubulin inhibitor 64 S1P receptor 64 papillary renal cell carcinoma 64 murine models 64 MMP inhibitors 64 genetic loci 64 aromatase inhibitors AIs 64 mutated K ras 64 alpha fetoprotein AFP 64 differentiated thyroid 64 teratogens 64 PARP inhibition 64 epithelial ovarian cancer 64 BEXXAR Therapeutic Regimen 64 imatinib resistance 64 radiolabeled TM# 64 nonmelanoma skin cancers 64 prognostically 64 EGFR mutation status 64 HCV protease inhibitors 64 prostate carcinoma 64 histological subtypes 64 chromosomal mutations 64 proliferative disorders 64 beta1 integrin 64 EGFR inhibitors 64 pharmacodynamic parameters 64 urothelial carcinoma 64 Genetic variations 64 microtubule inhibitor 64 CYP#D# gene 64 cytotoxic therapies 64 peptide antigens 64 kidney urologic 64 pre malignant lesions 64 chemoresistant 64 tumorigenicity 63 proteasome inhibitors 63 chlamydial 63 predictive biomarkers 63 dasatinib Sprycel 63 LRP5 63 coinfected patients 63 relapsed ovarian cancer 63 DNA methylation patterns 63 ALK inhibitors 63 epigenetic therapies 63 Zolinza 63 APOE genotype 63 immune modulating 63 trastuzumab Herceptin ® 63 Genetic variants 63 basal cell carcinoma BCC 63 pharmacodynamic biomarkers 63 anti fibrotic 63 Estrogen Receptor 63 effector function 63 germline mutations 63 K ras mutation 63 Clusterin 63 panobinostat 63 IGF IR 63 antimetabolites 63 EGFR therapies 63 CYP#D# genotype 63 EndoTAGTM 1 63 pulmonary metastases 63 retaspimycin 63 mucinous 63 precursor lesions 63 anti leukemic 63 recurrent glioblastoma multiforme 63 pathogenic mechanisms 63 Cardiotoxicity 63 EGFR HER2 63 p# biomarker 63 EGFR inhibition 63 HER2 positive metastatic breast 63 ENMD # 63 gastrointestinal stromal tumors GISTs 63 protein tyrosine phosphatases 63 KRAS status 63 antiplatelet medications 63 miRNA biomarkers 63 Src inhibitors 63 prognostic marker 63 chromosomal rearrangement 63 myelofibrosis polycythemia vera 63 inhibit metastasis 63 CD# antibodies 63 LHRH antagonists 63 thyroid carcinoma 63 Blinatumomab 63 missense mutations 63 hormonally sensitive 63 CDK4 63 recurrent ovarian 63 TMPRSS2 ERG fusion 63 prognostic indicator 63 ABCB1 gene 63 somatic mutations 63 serum biomarkers 63 hematopoietic malignancies 63 receptor tyrosine kinase inhibitor 63 inhibiting tumor 63 mutated BRAF gene 63 HGS ETR2 63 clinicopathologic 63 malignant ovarian 63 prognostic biomarkers 63 EGFR mutant 63 Vidaza ® 63 carcinoid tumors 63 acute leukemias 63 aneuploid cells 63 NPM1 mutation 63 FGFR2 63 diagnostic biomarkers 63 Cathepsin B 63 miRs 63 #F FDG PET 63 factor TNF 63 cathepsins 63 taxane therapy 63 S. maltophilia 63 pancreatic lung 63 plasma kallikrein 63 atypical hyperplasia 63 Epidermal Growth Factor Receptor 63 lymphomas leukemias 63 unresectable tumors 63 Virulizin ® 63 Squamous 62 liposomal doxorubicin 62 Myelodysplastic syndromes MDS 62 follicular lymphoma FL 62 malignant pancreatic 62 seminomas 62 fibrotic disease 62 invasive lobular 62 gastric adenocarcinoma 62 activating mutations 62 Enzastaurin 62 mutational analysis 62 chemopreventive agents 62 preclinically 62 ABCB1 62 multitargeted 62 tigecycline 62 transgene expression 62 Pseudomonas aeruginosa infections 62 5alpha reductase 62 ovarian pancreatic 62 EGFR mutations 62 serous ovarian cancer 62 vinca alkaloid 62 microdeletions 62 VKORC1 62 T#I [002] 62 carcinoids 62 mechanistic studies 62 GIST tumors 62 leiomyomas 62 antitumour 62 BCR ABL mutations 62 prognostic significance 62 florbetaben 62 breast endometrial 62 isotypes 62 phenotypic expression 62 neuroendocrine cancers 62 thalidomide Thalomid 62 colorectal gastric 62 humanised antibody 62 alvespimycin 62 immunosuppressive regimens 62 NMDA antagonists 62 immuno modulatory 62 baseline LDH 62 lymphoproliferative disorders 62 immune suppressive 62 prostate cancer PCa 62 genotypic resistance 62 HbF 62 locoregional 62 pleiotropic 62 androgen receptor AR 62 relapsed MM 62 PXD# 62 chemosensitivity 62 cytoprotective 62 Leukemias 62 PCA3 gene 62 antitumoral 62 cardio metabolic diseases 62 selective modulator 62 Li Fraumeni 62 osteosarcomas 62 TGFBR1 * 6A 62 polycythemia vera PV 62 FLT3 62 pertuzumab 62 cMET 62 selectively inhibited 62 Papillary 62 liver metastasis 62 tumoral 62 micrometastases 62 MGd 62 stratifying patients 62 NF kB pathway 62 favorable pharmacokinetic profile 62 distant metastasis 62 imatinib Gleevec 62 AEG# 62 hypereosinophilic syndrome 62 demonstrated antitumor activity 62 immunomodulation 62 circulating endothelial cells 62 mTOR inhibition 62 IGF 1R 62 malignant nodules 62 antiproliferative 62 preferentially bind 62 pharmacodynamic properties 62 cytolytic 62 pDCs 62 mutated KRAS gene 62 NKX#.# 62 COX2 62 genetic variants associated 62 M. pneumoniae 62 estrogen receptor beta 62 MAPK pathway 62 delafloxacin 62 Leydig cell 62 BRCA deficient 62 hepatoma 62 Treg cell 62 erlotinib Tarceva ® 62 selective inhibition 62 nonalcoholic steatohepatitis NASH 62 Immunohistochemical analysis 62 anti atherogenic 62 PPARgamma 62 chromosome #p#.# 62 prostate carcinogenesis 62 anticancer therapies 62 subclinical disease 62 predictive biomarker 62 immunohistochemical 62 Squalamine 62 urothelial bladder cancer 62 pharmacodynamic PD 62 Bleomycin 62 eTag assays 62 protein kinase inhibitors 62 cyclin dependent kinase inhibitor 62 antisense inhibitors 62 Azedra 62 sarcomatoid 62 cranial irradiation 62 somatostatin receptors 62 heparanase 62 endometrial hyperplasia 62 ERK signaling 62 A3 adenosine receptor 62 colorectal carcinogenesis 62 TOP2A 62 PKC inhibitors 62 sorafenib tablets 62 fluoropyrimidine 62 ZNF# 62 receptor inhibitor 62 potent anti angiogenic 62 medically inoperable 62 immunoregulatory 62 RRM1 62 HERmark assay 62 K ras 62 estrogen receptor ER 62 antagomirs 62 mammographic density 62 MGUS 62 genetic aberrations 62 tamoxifen Nolvadex ® 62 TRAIL induced apoptosis 62 clade B 62 ADVEXIN therapy 62 immune dysregulation 62 anthracycline chemotherapy 62 c KIT 61 pro angiogenic 61 mutated p# 61 therapeutically relevant 61 OMP #M# 61 lobular carcinoma 61 novel VDA molecule 61 miRview ™ squamous 61 CCX# 61 Hedgehog inhibitor 61 Aplidin R 61 differential gene expression 61 Candida infection 61 CIN2 + 61 etiologic factors 61 chromosome aberrations 61 investigational therapies 61 E#F# 61 urothelial cancer 61 #beta HSD 1 61 ductal carcinomas 61 IAP inhibitor 61 V#F mutation 61 MR spectroscopy 61 TLE3 61 lymphoid malignancies 61 nonvaccine 61 pleiotropic effects 61 NPM1 mutations 61 acadesine 61 antineoplastic agents 61 genomic biomarkers 61 premalignant 61 percutaneous biopsy 61 extramedullary 61 HCV replicon 61 vascular disrupting agents 61 carcinoid 61 cervical lymph nodes 61 GRNOPC1 contains 61 clinico pathological 61 metabonomics 61 refractory prostate cancer 61 cilengitide 61 Darinaparsin 61 MDR1 61 dyslipidaemia 61 thyroid nodules 61 methylation markers 61 irinotecan oxaliplatin 61 Afatinib 61 antidiabetic drugs 61 mesenchymal cell 61 thiopurine 61 TCF#L# 61 therapeutic regimens 61 PTPN# 61 antitumor efficacy 61 signaling cascades 61 pituitary adenomas 61 Vorinostat 61 colorectal adenoma 61 antiestrogen 61 temozolomide TMZ 61 Metastatic colorectal cancer 61 AKT inhibitor 61 GSTP1 61 mda 7 61 anti mitotic 61 trabectedin 61 EpCAM 61 PCa 61 oncogenic mutations 61 Temsirolimus 61 Cloretazine R 61 histone deacetylase HDAC 61 GISTs 61 Bcr Abl mutations 61 aerodigestive tract 61 Incretin mimetics 61 Hepatocellular Carcinoma HCC 61 testicular germ cell 61 Adjuvant chemotherapy 61 kinase inhibitors 61 adipogenic 61 EGFR mutation 61 HER2 receptor 61 metastatic RCC 61 Darapladib 61 oligodendrogliomas 61 small molecule activators 61 myeloproliferative disorders 61 N. gonorrhoeae 61 recurrent glioblastoma multiforme GBM 61 hematological malignancy 61 immunotherapeutic approaches 61 myelomas 61 gene polymorphisms 61 antiplatelet therapies 61 fibrate drugs 61 skeletal metastases 61 oesophageal adenocarcinoma 61 Fas ligand 61 adrenocortical cancer 61 tumorigenic 61 cytolytic activity 61 Pathway Inhibitor 61 S/GSK# 61 bladder tumors 61 mammary stem cells 61 serotonin receptor 61 pulmonary hypertension PH 61 malignant lymphomas 61 mammographically 61 pharmacologic intervention 61 renal cell carcinomas 61 hamartomas 61 Surgical resection 61 HLA DQ2 61 JAK2 enzyme 61 anti CD3 61 potently inhibit 61 PI3K Akt 61 progesterone receptor PR 61 Hurthle cell 61 GSK3B 61 fusion enhancers 61 radioimmunotherapy RIT 61 metastatic lesions 61 FGFR 61 Sjögren syndrome 61 mapatumumab 61 microRNA biomarkers 61 neoplastic lesions 61 nutlin 3a 61 overlapping toxicities 61 Hsp# inhibition 61 chemoprevention trials 61 colorectal lung 61 biphosphonates 61 antiandrogens 61 amyloid plaque formation 61 adenocarcinomas 61 CTAP# Capsules 61 arterial calcification 61 monoclonal antibody therapies 61 prognostic variables 61 System IPSS 61 pheochromocytoma 61 VEGF inhibitors 61 novel peptide 61 JAK inhibitors 61 ansamycin 61 Pertuzumab 61 antiangiogenic 61 neoplastic 61 adjuvant therapies 61 metabolomic profiles 61 NS4A 61 treating neuropathic pain 61 oncogenic transformation 61 BMS# 61 tumor hypoxia 61 BRAF V#E mutation 61 colorectal tumor 61 anticancer treatments 61 cardioprotective effects 61 direct thrombin inhibitors 61 Xanafide 61 hypoxic tumors 61 bisulfite sequencing 61 JAK2 inhibitor 61 farletuzumab 61 multicentric 61 YONDELIS 61 progesterone receptor 61 histone acetylation 61 Fibroblast Growth Factor Receptor 61 drug metabolizing enzymes 61 Anthracycline 61 MTHFR 61 pan HDAC inhibitor 61 Acute myeloid leukemia 61 Anticalins R 61 node metastases 61 plasma lipid 61 neuroinflammatory 61 serologic tests 61 familial pancreatic cancer 61 Pim kinases 61 vorinostat 61 uricase 61 micrometastasis 61 haematopoietic 61 histologic subtypes 61 p# Shc 61 microRNA expression 61 radiosensitive 61 HIF PH inhibitors 61 p# biomarkers 61 Zevalin consolidation 61 T1DM 61 endophenotypes 61 gastric carcinoma 61 TPMT 61 Lymph node 61 thromboembolic disease 61 acute myeloid 61 anti androgens 61 favorable pharmacokinetic 61 stimulate neurogenesis 61 cytotoxics 61 CXCL5 61 Deforolimus 61 endogenous estrogen 61 SSc 61 AT1R 61 Aurora kinase 61 PTEN mutations 60 neovascular diseases 60 H#K#me# 60 TLR antagonists 60 pharmacodynamic effects 60 promoter hypermethylation 60 cytopathic 60 CanAg 60 B7 H4 60 castrate resistant 60 genotypic 60 Fibroblast 60 metastatic uveal melanoma 60 operable breast cancer 60 virulence genes 60 anti amnesic 60 bioinformatic approaches 60 deacetylase inhibitors 60 cyclin E 60 Thiovir 60 genomic biomarker 60 telomerase inhibitor 60 gamma secretase inhibitors 60 invasive ductal 60 PI3K inhibitors 60 heavily pretreated 60 HGS# 60 therapeutic monoclonal antibody 60 indibulin 60 Colon polyps 60 mutational status 60 HBeAg negative 60 pharmacodynamic endpoints 60 interferon IFN 60 Sphingomab 60 synthetic lethality 60 spontaneous regression 60 EBV infection 60 pharmacological approaches 60 fosbretabulin 60 HER2 positivity 60 hereditary predisposition 60 ovarian breast 60 HDACi 60 clinically localized prostate 60 cardiac glycosides 60 colorectal carcinoma 60 Angiolix 60 biologic pathway 60 triterpenoids 60 miRNA expression patterns 60 Carfilzomib 60 lymphotoxin 60 Gefitinib 60 histone deacetylation 60 nonsmall cell lung cancer 60 immunotoxin 60 selective inhibitors 60 anticancer agents 60 neoplastic cells 60 colorectal tumors 60 follicular dendritic cells 60 core needle biopsies 60 CDH1 60 molecular biomarker 60 ependymomas 60 inhibit angiogenesis 60 #T# L1 60 lymphoma subtypes 60 peptidic 60 gene loci 60 selective agonists 60 immunohistochemical analysis 60 act synergistically 60 biologic plausibility 60 FSH receptor 60 Cytotoxic 60 ritonavir boosted protease inhibitor 60 DHFR 60 pilocytic astrocytomas 60 MiCK assay 60 benzimidazole 60 doxorubicin Adriamycin 60 benign moles 60 PI3K/mTOR 60 atherothrombotic 60 HER2 amplification 60 phenotyping 60 HDAC inhibition 60 c MYC 60 HPV genotypes 60 carotid plaques 60 narcolepsy cataplexy 60 ductal breast cancer 60 immunomodulating 60 virotherapy 60 pharmacologic stress 60 FDG PET 60 mycophenolate mofetil 60 metastatic colorectal 60 p# activation 60 echinocandins 60 p# mutations 60 metastatic gastric 60 N glycan 60 Factor Receptor 60 Vidofludimus 60 poly ADP ribose polymerase 60 mutant KRAS 60 ERBB2 60 prospective observational studies 60 HCV replication 60 novel anticancer 60 eIF 4E 60 MET amplification 60 lymphoid cells 60 metastatic bladder 60 VDAs 60 DNA methyltransferases 60 LNP formulations 60 mTOR mammalian target 60 erythropoietic 60 colon carcinoma 60 telomere lengths 60 metalloprotease 60 coinfection 60 insulin sensitizing 60 obstructive coronary artery 60 vemurafenib 60 prostanoid 60 chimeric monoclonal antibody 60 vinca alkaloids 60 alefacept 60 ductal adenocarcinoma 60 solithromycin 60 HLA DR4 60 HCV antibody 60 Akt activation 60 GPC5 60 advanced metastatic renal 60 druggable target 60 erlotinib Tarceva 60 M2 subunit 60 Akt inhibitor 60 metabolomic profiling 60 postmenopausal hormone 60 PSN# [002] 60 gene locus 60 tumor xenograft models 60 Subgroup analyzes 60 busulfan 60 CagA 60 alkylating 60 replicon 60 OXi# 60 CB1 antagonists 60 pancreatic endocrine 60 antiepileptics 60 K RAS 60 thrombophilia 60 MYCN amplification 60 renal fibrosis 60 annexin 60 familial clustering 60 antithrombotic agents 60 nonmetastatic 60 tumor necrosis 60 Protein Kinase C 60 acute promyelocytic leukemia APL 60 antiresorptive 60 XL# inhibits 60 nanomolar 60 airway responsiveness 60 Bcr Abl inhibitors 60 MDSCs 60 hormonally responsive 60 presymptomatic 60 FDG PET imaging 60 pharmacogenetic testing 60 cerebral microbleeds 60 diabetic retinopathy DR 60 methylation patterns 60 HuLuc# 60 cervical lesions 60 Apo2L 60 Seliciclib 60 protein tyrosine phosphatase 60 reverse transcriptase inhibitors 60 empiric therapy 60 Cyclin E 60 BRCA1 BRCA2 60 atherothrombosis 60 ACAT2 60 nicotinic acetylcholine receptor 60 GBMs 60 prostate carcinomas 60 AChE inhibitors 60 PPARγ 60 Immunohistochemical staining 60 AMACR 60 metaglidasen 60 Vidaza azacitidine 60 Cdc7 60 immune modulators 60 testicular tumors 60 progesterone receptor negative 60 thyrotropin 60 gastrointestinal stromal tumor GIST 60 PDGF receptor 60 DFMO 60 fulvestrant 60 intravenous bisphosphonates 60 triphendiol 60 dihydrofolate reductase 60 Onconase 60 chromosomal aberrations 60 Hsp# inhibitors 60 miR #b [002] 60 Medullary thyroid cancer 60 intracellular bacteria 60 Dr. Bezprozvanny 60 Therapeutic antibodies 60 signal transduction inhibitors 60 incidentalomas 60 immunosuppressant therapy 60 SPINK1 60 pain palliation 60 BRAF inhibitors 60 β blockers 60 Genetic variation 60 fluconazole resistant 60 Epstein Barr Virus EBV 60 EGFR activating mutations 60 preoperative chemotherapy 60 PPARg 60 Angiotensin converting enzyme 60 TT genotype 60 Immunomodulatory 60 PPAR gamma agonists 60 trastuzumab resistant 60 aberrant activation 60 small molecule agonists 60 demyelinating 60 modifier genes 60 metaplasia 60 tanespimycin 60 virologic responses 60 epigenetic therapeutics 60 chemopreventive 60 anti angiogenic therapy 60 cediranib 60 adenomatous polyps 60 etiological 60 cisplatin chemotherapy 60 induce apoptosis 60 apoptosis inducing 60 PDE#A 60 vitro assay 60 nonnucleoside reverse transcriptase inhibitors 60 ALK inhibitor 60 WT1 60 MT1 MMP 60 Teriflunomide 60 leukemia multiple myeloma 60 antiangiogenic drugs 60 Mechanistic studies 60 Arranon 60 IDH1 mutations 60 inhibitory effects 60 nucleoside analog 60 deacetylation 59 HepDirect prodrug 59 KRAS gene mutations 59 metastatic prostate 59 non coding RNA 59 Cryptococcus neoformans 59 perilipin 59 riociguat 59 hedgehog pathway 59 enzastaurin 59 Endometrial cancer 59 metabolizing enzymes 59 JAK2 inhibitors 59 serum GGT 59 receptor subtypes 59 antineoplastic 59 eotaxin 59 LAB CGRP 59 Upregulation 59 oncogenesis 59 NNRTI resistance 59 myeloproliferative neoplasms MPNs 59 DACH platinum 59 methylated DNA 59 allogeneic HSCT 59 hMG 59 lipid abnormalities 59 potent cytotoxic 59 ovarian lung 59 phosphate S1P 59 Antiangiogenic 59 somatostatin 59 SIRT2 59 Aplidin 59 HER2 neu 59 alpha#beta# integrin 59 CEA CD# Her2 59 γ secretase 59 tumor biopsies 59 PITX2 methylation 59 AKT1 mutation 59 monogenic 59 breast lesions 59 potent antitumor activity 59 breast cancer metastasis 59 bladder ovarian 59 FGFR4 59 GVAX Pancreas Vaccine 59 Mitomycin C 59 ADPKD 59 lenalidomide dexamethasone 59 HER2 gene 59 epigenetic mechanisms 59 carbohydrate polymers 59 PCNSL 59 Tyrima 59 TNF α 59 colorectal liver metastases 59 granzyme B 59 mutant BRAF 59 neurocognitive impairment 59 Panzem R NCD 59 neoadjuvant treatment 59 RAF kinase 59 bioactive lipids 59 HG PIN 59 malignant prostate 59 glioma cells 59 lesional 59 interferon lambda 59 breast carcinomas 59 hematological parameters 59 null responder 59 gp# protein [002] 59 Anticalins ® 59 prostate abnormalities 59 genomic rearrangement 59 CCR5 inhibitor 59 pancreatic ductal adenocarcinoma 59 endothelin receptor 59 endogenous ligands 59 gemcitabine Gemzar 59 hormone receptor negative 59 ALB # 59 infecting organism 59 MC1R 59 fluoroquinolone resistance 59 RNAi therapeutic targeting 59 grade gliomas 59 tyrosine kinase inhibitor 59 uPAR 59 malignant pleural mesothelioma 59 VIPR2 59 neuronal nicotinic receptor NNR 59 CCR5 antagonists 59 HIV protease 59 E. faecalis 59 oncologic outcomes 59 Gag polymorphisms 59 Platinol ® cisplatin 59 HMGCR 59 serum PTH 59 gene amplification 59 ASCUS 59 CSF biomarkers 59 differentially expressed genes 59 thyroid nodule